A new $7.6 million grant from the National Institutes of Health, or NIH, will expand rare disease research and clinical care rooted in the story of Marley Berthoud, a Michigan child whose diagnosis helped scientists identify Bachmann-Bupp Syndrome and discover a new treatment.
When Marley was born in 2015, her mother and father, Kelly and Brian Berthoud, knew instantly that something was wrong. Marley suffered from low muscle tone, developmental delays, complete hair loss and difficulty regulating her blood sugar and body temperature.
After four years of searching for answers, genetic testing by Caleb Bupp, M.D., at Corewell Health Helen DeVos Children's Hospital and molecular research by André Bachmann, PhD, at the Michigan State University College of Human Medicine identified a mutation in Marley's ODC1 gene. Her case established the first recognized diagnosis of Bachmann-Bupp Syndrome.
Bachmann drew on decades of ODC1 protein research to identify difluoromethylornithine, or DFMO, as a way to "turn down" Marley's overactive protein. The existing medication has long been used to treat West African sleeping sickness. In late 2019, 4-year-old Marley became the first person in the world treated with DFMO by Bupp and his genetics team for the condition.
Within months of beginning treatment, Marley's hair, eyelashes and eyebrows grew back. She sat independently, gained strength and made cognitive progress. Today, 11-year-old Marley communicates using an iPad, understands instructions and enjoys time with her family.
This milestone proved that bridging the gap between laboratory research and bedside care could open new doors for families of children with rare diseases who felt like they had no medical options. This important alignment now has been recognized by NIH with a new $7.6 million NIH U54 grant awarded jointly to Corewell Health and the MSU College of Human Medicine. Other key partners include Johns Hopkins University and Snyder-Robinson Foundation.
Lab-clinic partnership drives discovery
I'm a scientist and university professor, not a physician. There is no way I could do this without Dr. Bupp and his team at Corewell Health because they are the ones who care for the patients. At the same time, they could never have done this without our academic laboratory expertise. It is a mutually beneficial partnership, and neither of us would have achieved this alone."
André Bachmann, PhD, Michigan State University College of Human Medicine
Translating years of lab experiments into real-world patient progress brought a profound sense of purpose to the entire research team.
"It is so fulfilling when you see your laboratory research translate directly into helping a child at the clinic," Bachmann added. "When we first saw Marley, she had no muscle tone, couldn't sit up and needed a feeding tube. Today, she is communicating, taking steps and enjoying her life. Seeing a safe medication bring back a child's strength and hair - and giving her family hope - goes beyond anything we could have imagined. This new grant lets us expand that hope to families everywhere with children who have Bachmann-Bupp Syndrome, Snyder-Robinson Syndrome or other related polyamine disorders."
Bupp agreed that Marley's story created a ripple effect that could help countless other families navigating rare genetic diagnoses.
"All of this work has been so rewarding because it started with a single patient," he said. "From a human standpoint, I don't think there's a better way to spend research funds than on rare diseases, because what you learn in rare diseases, you can then expand to help so many others. This new grant comes at a beautiful point for us to take what we have built together over almost 10 years and change the direction steeply toward expanding this to help more patients and families."
For Kelly and Brian, seeing Marley thrive has given her family a level of peace they once thought was impossible.
"Wholeheartedly, I believe that we would not be at the comprehension that we have without the medication," Kelly shared. "As a parent, I know without a doubt that she's happy she's here and she enjoys her life. I could not ask for anything more."
Grant expands research and clinical care
The funding will support the Center for Polyamine Disorders, founded by Bupp and Bachmann in 2017. Corewell Health and MSU will lead the grant project in partnership with Johns Hopkins University, the Snyder-Robinson Foundation and six clinical sites. Together, they will be part of the NIH Rare Diseases Clinical Research Network, a national network of 20 research centers.
To date, five patients worldwide have experienced improvement in key symptoms through DFMO treatment provided through the center, and 24 children globally have been diagnosed with Bachmann-Bupp Syndrome.
The grant will enable researchers to:
- Complete clinical research and long-term studies needed to pursue FDA approval of DFMO for Bachmann-Bupp Syndrome.
- Apply lessons from existing treatments to develop diagnostic tools and therapies for four related rare genetic conditions.
- Establish six clinical sites and provide education, screening options and guidance to help pediatricians recognize rare symptoms earlier.
- Fund pilot studies and train physicians and researchers focused on rare disease care.
A model for rare disease collaboration
The work brings together laboratory scientists, physicians, families and advocacy organizations, including the Snyder-Robinson Foundation and the nonprofit Every Cure. Their collaboration keeps research connected to the needs of children and families while extending discoveries from one condition to related disorders.
For the Berthoud family, the research is personal. Today, Marley gets to enjoy many of the same things as her peers; high-fives, spending time with her younger brother Jack and sharing her smile with everyone she meets.
"We all want our children to do great things in the world, and she's doing it at a younger age than a lot of kids," Kelly said. "She's had a profound impact on the medical community and the research community just because she was born. I would love for the team at the NIH to know that they entrusted this money to the greatest humans on earth. The world is seeing that they're changing how medicine works and how research and care can work together."